» Articles » PMID: 7660803

[Relationship Between the Molecular Composition of C1027, a New Macromolecular Antibiotic with Enediyne Chromophore, and Its Antitumor Activity]

Overview
Journal Yao Xue Xue Bao
Specialties Pharmacology
Pharmacy
Date 1995 Jan 1
PMID 7660803
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The molecule of C1027, an antitumor antibiotic with extremely potent cytotoxicity against cultured cancer cells, is composed of an enediyne chromophore and an apoprotein of 10.5 kDa. These two parts of the molecule, connecting each other through non-covalent binding, can be dissociated and reconstituted. As determined by clonogenic assay, the chromophore served as the active part of the molecule, displaying potent cytotoxicity similar to that of intact C1027. The activity of free chromophore decreased more rapidly than that of intact C1027, indicating that apoprotein played a role in protecting the chromophore from inactivation. By incubating together in phosphate buffer, the chromophore and apoprotein were reconstituted to form an intact C1027. The ratio of chromophore and apoprotein remained 1 : 1 in the reconstituted molecule, even though extra amount of chromophore was added. The optimal condition for the reconstitution was pH 7.0, at 20 degrees C for 12 h. When the disulfide bond of the apoprotein was reduced by DTT, the activity of C1027 decreased more rapidly. C1027 was digested by pronase and the produced fragments of various molecular weights were examined by capillary electrophoresis. The cytotoxicity of 3-5 kDa fragment approximated that of intact C1027 and its IC50 value was 0.07 fmol.L-1. The results indicate that the intactness of the apoprotein is not indispensable for stabilizing the chromophore and a smaller molecule of 3-5 kDa consisting of a peptide fragment and a chromophore may retain full C1027 activity.

Citing Articles

A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer.

He S, Zhao C, Tao H, Sheng W, Gao R, Liu X Drug Deliv. 2022; 29(1):1243-1256.

PMID: 35416106 PMC: 9048960. DOI: 10.1080/10717544.2022.2063454.


An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy.

Xu J, Liu X, Li L, Zhang S, Li Y, Gao R Oncotarget. 2015; 6(28):26322-34.

PMID: 26314845 PMC: 4694904. DOI: 10.18632/oncotarget.4709.


Tuftsin-based, EGFR-targeting fusion protein and its enediyne-energized analog show high antitumor efficacy associated with CD47 down-regulation.

Liu W, Liu X, Li L, Li Y, Zhang S, Zhen Y Cancer Immunol Immunother. 2014; 63(12):1261-72.

PMID: 25164878 PMC: 11029470. DOI: 10.1007/s00262-014-1604-1.


Small antibody fusion proteins with complementarity-determining regions and lidamycin for tumor targeting therapy.

Zhong G, Wu M, Guo X, Xu Z, Zhang S, Zhen Y Oncol Lett. 2013; 5(4):1183-1188.

PMID: 23599760 PMC: 3629231. DOI: 10.3892/ol.2013.1143.


Lidamycin shows highly potent cytotoxic to myeloma cells and inhibits tumor growth in mice.

Zhen Y, Lin Y, Li Y, Zhen Y Acta Pharmacol Sin. 2009; 30(7):1025-32.

PMID: 19575006 PMC: 4006655. DOI: 10.1038/aps.2009.75.